University of Texas's MD Anderson Cancer: Long-Term Benefit of SABR for Operable Early-stage NSCLC Shown in New Study
September 15, 2021
September 15, 2021
HOUSTON, Texas, Sept. 15 (TNSJou) -- The University of Texas's MD Anderson Cancer Center issued the following news release:
A new study from researchers at The University of Texas MD Anderson Cancer Center showed that stereotactic ablative radiotherapy (SABR) was as effective as surgery at providing long-term benefits to patients with operable early-stage non-small cell lung cancer (NSCLC) and generated minimal side effects. The study is the first of its kind to compare long-te . . .
A new study from researchers at The University of Texas MD Anderson Cancer Center showed that stereotactic ablative radiotherapy (SABR) was as effective as surgery at providing long-term benefits to patients with operable early-stage non-small cell lung cancer (NSCLC) and generated minimal side effects. The study is the first of its kind to compare long-te . . .